Nuvation Bio is focused on developing and commercializing oncology therapies, with taletrectinib as its lead asset. The company aims to fund U.S. commercialization of taletrectinib, if approved, and continue development of its clinical-stage pipeline. Management says the financings provide a path to potential profitability without the need for additional capital. Nuvation expects to be positioned to launch taletrectinib in mid-2025, subject to FDA approval. The transactions strengthen the company’s balance sheet and increase flexibility to pursue strategic opportunities. TD Cowen served as financial advisor and Cooley served as legal advisor to Nuvation Bio. Nuvation Bio is a stealth-mode biopharmaceutical company focused on developing next-generation therapies to address unmet needs in oncology. Its proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. The company intends to use new capital to expand its development activities and advance a number of its oncology programs. Nuvation’s executive team includes former senior leaders from Medivation alongside newly appointed senior scientists and clinical leaders. The company was founded in 2018 and operates out of New York City. Nuvation recently closed a major financing to fund its pipeline expansion.

Total raised

$375M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Mar 2025